Yakira Capital Management criticized Atrium Therapeutics for raising $50 million in equity at a deeply discounted price after its shares fell 44%, arguing this move dilutes shareholder value. Yakira highlights that Atrium's stock trades below its net cash value alone, ignoring potential worth from its Bristol Myers Squibb collaboration and internal drug pipeline. They call on Atrium's Board to immediately conduct a strategic review, consider partnerships or a sale, and control spending to protect shareholders before further cash burn and dilution occur. Yakira also questions why a rights offering wasn't used to allow existing shareholders to participate and urges transparency on capital needs for clinical milestones expected in late 2027.
Atrium Therapeutics is the subject of this report. For readers following Health-sector stocks, here is Pluang's market snapshot as of Oct 20, 2026 19:03 WIB: Out of 150 priced US Health stocks, 81 rose and 62 fell today. Notable movers include ENVB at USD 1.34 with a 4.96% decline and 100% sell orders, MMED at USD 17.17 down 3.49%, and TWST at USD 135.39 up 3.13% with 100% buy orders. Typical hold times range from 11 to 27 days on Pluang.
RoyaLand Company Ltd. announced Palazzo Chronicles, a free-to-play mobile match-3 puzzle game set in 19th-century Piedmont during Italy's reunification. Players help Adelaide restore her inherited family castle by solving puzzles and rebuilding rooms...
Route 92 Medical has secured a $100 million senior secured debt facility from Trinity Capital to strengthen its balance sheet and support ongoing product innovation and commercial growth. The funding will help the company expand its neurovascular int...
First Federal Savings Bank marks its 122nd anniversary, highlighting over a century of service to Southwest Indiana and Western Kentucky. The bank has grown from a single community institution to ten locations, focusing on personal service, local dec...
Aclarion, Inc. announced an 85% year-over-year increase in scan volumes for Q3 2026, contributing to a 117% growth for the first nine months of the year. The company highlighted the publication of supportive clinical data in the European Spine Journa...
The global electric vehicle (EV) components market is projected to grow from $486.4 billion in 2026 to $1.28 trillion by 2036, expanding at a 10.2% CAGR. Growth is fueled by rising EV adoption, advancements in battery systems, power electronics, and ...
